ANAB
Anaptysbio, Inc Health Care Pharmaceutical Preparations Russell 3000
$48.28Close
$1.4BMarket cap
$22.06 – $69.8152-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 31% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
31%
1wk
down 0.9%
price change
1mo
down 3.9%
price change
12-month return
up 99%
market up 11% ·
its own up 90%
F-score
—
— Not assessed
Altman Z
3.24
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
36.4×
price / book
Earnings yield
up 18.7%
EBIT / enterprise value
Cheaper than
44%
of the market · around average
Revenue growth
up 157%
year on year
EPS growth
—
latest quarter
Sales growth
up 23%
latest quarter · +31 pts
ROE
down 24%
return on equity
Free cash margin
up 8%
$19.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-0.6×
net cash
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- FCF turned positive ($-136M → $20M)
Trade setup
ATR%
4.7%
$2.25 a day · 2×ATR $43.77
RS
78 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.61
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
May 12, 2026
Last shock
Jul 15, 2026-11% in one session2.3× volumeno filing matched-14% since
Financials
- Net -6%
- Free cash 8%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $234.6M |
| Operating income | -$23.9M | -$56.8M | -$115.2M | -$164.4M | $66.2M | $226.9M |
| Net income | -$19.9M | -$57.8M | -$128.7M | -$163.6M | -$145.2M | -$13.2M |
| Net margin | -27% | -91% | -1251% | -954% | -159% | -6% |
| Earnings per share | -$0.73 | -$2.11 | -$4.57 | -$6.08 | -$4.92 | -$0.44 |
| Free cash flow | -$14.7M | -$47.3M | -$74.0M | -$121.6M | -$135.7M | $19.6M |
| Free cash margin | -20% | -75% | -719% | -709% | -149% | 8% |
| Cash | $250.5M | $495.7M | $71.3M | $36.0M | $23.1M | $138.2M |
| Shareholders' equity | $396.7M | $356.4M | $262.1M | $88.1M | $70.9M | $37.2M |
| Shares outstanding | 27.36m | 27.65m | 28.51m | 26.60m | 30.47m | 28.02m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Sep 21, 2026 | Annual ↗ | Jun 30, 2026 | 83d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 3, 2026 | Annual ↗ | Dec 31, 2025 | 62d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 5, 2025 | Quarterly ↗ | Mar 31, 2025 | 35d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 5, 2024 | Quarterly ↗ | Jun 30, 2024 | 36d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 11, 2024 | Annual ↗ | Dec 31, 2023 | 71d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 21, 2026 | Exhibits only ↗ |
| Aug 11, 2026 | Shareholder vote ↗ |
| Jul 30, 2026 | Regulation FD ↗ |
| Jun 22, 2026 | Material agreement ↗ |
| May 29, 2026 | Regulation FD ↗ |
| May 21, 2026 | Charter or bylaws ↗ |
| May 12, 2026 | Results ↗ |
| May 11, 2026 | Director or officer change ↗ |
| Apr 20, 2026 | Material agreement · Acquisition or disposal · Director or officer change · Other events ↗ |
| Mar 27, 2026 | Material agreement · Agreement ended · Director or officer change · Regulation FD ↗ |
| Mar 3, 2026 | Results · Regulation FD ↗ |
| Jan 9, 2026 | Results · Regulation FD ↗ |